[go: up one dir, main page]

WO1997038701A1 - Composition et procede pour le traitement du syndrome premenstruel - Google Patents

Composition et procede pour le traitement du syndrome premenstruel Download PDF

Info

Publication number
WO1997038701A1
WO1997038701A1 PCT/CA1996/000229 CA9600229W WO9738701A1 WO 1997038701 A1 WO1997038701 A1 WO 1997038701A1 CA 9600229 W CA9600229 W CA 9600229W WO 9738701 A1 WO9738701 A1 WO 9738701A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
magnesium
present
diuretic
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1996/000229
Other languages
English (en)
Inventor
Simon W. Rabkin
Original Assignee
Neotech Medical Innovations In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotech Medical Innovations In filed Critical Neotech Medical Innovations In
Priority to PCT/CA1996/000229 priority Critical patent/WO1997038701A1/fr
Priority to AU52655/96A priority patent/AU5265596A/en
Publication of WO1997038701A1 publication Critical patent/WO1997038701A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Definitions

  • the present invention relates to therapeutic compositions and methods and in particular compositions and methods for treatment of an individual exhibiting symptoms of premenstrual syndrome.
  • PMS premenstrual syndrome
  • PMS The specific etiology of PMS remains unknown, although many theories have been proposed. These include: hormonal imbalances, hormonal deficiencies, vitamin deficiencies, disturbances of the autonomic nervous system, salt and water imbalances, altered endogenous opiates and psychosomatic dysfunction.
  • M.Ferin, R.Jewelewicz and M.Warren The Menstrual Cvcle; Physiology. Reproductive Disorders, and Infertility, pp. 198-204 (1993).
  • PMS is multifactorial and probably also involves changes in neurohormones and neurotransmitters, which are not easily documented in humans. Numerous attempts have been made to develop an effective treatment for the symptoms of PMS. Dietary modification including reduction of salt, alcohol, and beverages containing caffeine have been suggested. Pharmacologic intervention is commonly used, especially progesterone therapy and hypothalamic-pituitary-ovarian axis suppressors.
  • Nonprescription pharmacologic compositions have also been made available. Most provide aspirin or acetaminophen as an analgesic for diminishing menstrual pain. Calcium has also been found to be an effective treatment, especially in regard to premenstrual pain and water retention. S.Thys-Jacobs,
  • Another object of the present invention is to provide a composition for the treatment of PMS symptoms that achieves enhanced compliance from the patient and therefore better results because each of the active ingredients required to treat the various symptoms are provided within a single formulation.
  • the present invention provides a method for treating premenstrual syndrome comprising administering an effective amount of calcium, magnesium, an analgesic and a diuretic so that the symptoms of premenstrual syndrome are reduced.
  • the present invention is also directed to a composition for the relief of pain and discomfort associated with premenstrual syndrome comprising and effective amount of calcium, magnesium, an analgesic and a diuretic.
  • composition according to the present invention is a formulation including at least four separate active ingredients: (1) magnesium; (2) calcium; (3) an analgesic; and (4) a diuretic.
  • Aspirin acetylsalicylic acid
  • acetaminophen acetaminophen
  • ibuprofen are each effective analgesics within the scope of the present invention.
  • the analgesic functions to relieve the symptoms of abdominal cramps, back pain and pain from swollen and tender breasts as well a ⁇ headache pain.
  • the analgesic acetaminophen is administered in a dose of about 500 mg. four times a day for a total of about 2000 mg/day.
  • the diuretic is provided to relieve symptoms related to water retention such a ⁇ excessive water weight, bloating, swelling, painful breasts, cramps and tension.
  • the preferred diuretic within the scope of the present invention is pamabrom, a theophylline derivative.
  • ammonium chloride, an acid-forming salt may be used.
  • caffeine is not a preferred diuretic since it tends to extend the symptoms of PMS rather than provide relief.
  • the diuretic is administered in a dose of about 25 mg four times a day for a total of about 100 mg/day.
  • Elemental magnesium (Mg 2+ ) is provided for relief of "negative affect" i.e. premenstrual mood fluctuations.
  • Mg cation supplementation must be sufficient to increase the cation content in both the lymphocytes and polymorphonuclear cells. This generally means a dosage higher than the recommended dietary allowances set by the National Academy of Sciences but low enough to avoid the risk of overload.
  • Applicant has determined that the magnesium cation be administered in a dose of about 100 mg of magnesium four times a day for a total of about 400 mg/day.
  • Preferred sources of magnesium ion for oral ingestion include magnesium glucoheptonate, magnesium pyrrolidone carboxylic acid, magnesium gluconate, magnesium pyroglutamate and magnesium sulfate.
  • Elemental calcium provides relief for both the physical and behavioral symptoms of PMS. Behavioral symptoms are generally characterized a ⁇ "negative affect”. Within the meaning of the present invention these include depression, violent tendencies, crying, mood swings, irritability and nervousness. Physical symptoms treated by the calcium therapy according to the present invention include headache, back pain, water retention, abdominal bloating and cramps, breast tenderness and fatigue. Applicant has determined that the calcium be administered in a dose of about 300 mg four times a day for a total of about 1200 mg/day.
  • the source of calcium for the formulation according to the present invention is in the form of calcium carbonate, calcium chloride, calcium glucoheptonate, calcium gluconate, calcium gluconogalactogluconate, calcium gluceptate, calcium lactate, calcium glubionate, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate and calcium phosphate tribasic.
  • Both the magnesium and calcium within the scope of the present invention must be in a form to allow the ions to be readily adsorbed by the body.
  • the above described calcium and magnesium compounds allow such absorption into the body.
  • Antacid agents are to be avoided since magnesium or calcium cations are less readily adsorbed from such compounds.
  • Example 1 The specific formulation set forth above produces optimal therapeutic results within the permissible deviation indicated. However, certain individual ingredients may vary in amount and still produce satisfactory results. The following specific examples are representative of the composition according to the present invention: Example 1
  • composition according to the present invention is effective in treating all the major symptoms of PMS by provide a broad therapeutic spectrum.
  • Each of the active ingredient ⁇ will address certain of the PMS symptoms.
  • the overlapping nature of the active ingredient ⁇ within the method and composition of the present invention enhances the effectiveness of treatment while at the ⁇ ame time compensating for deficiencies of a particular ingredient.
  • the magnesium will provide the greatest relief for water retention and negative affect. By itself, it has virtually no effect on the remaining symptoms.
  • calcium provides a broad-based treatment for every one of the symptoms; "negative affect” and water retention are only somewhat improved.
  • the analgesic component fills the remaining gaps in treatment, especially in regard to pain, headache and soreness while the diuretic targets water retention and its related symptoms.
  • a broad-based , therapeutic spectrum is achieved having improvements over the prior art methods and formulations.
  • Applicant believes that the present combination of active ingredients and method steps, especially those designed to address the same symptoms, produce a synergistic improvement in therapy over the individual ingredients alone. Since the applicant has selected active ingredients designed to address each of the various symptoms through different mechanisms of action, their cumulative effect produces improved treatment.
  • the formulation of the present invention may be incorporated within any suitable carrier known in the art, for example sucrose or dextrose. It may be in tablet or capsule form, in chewable or effervescent tablet or in liquid form. Further, the formulation may be prepared as a sustained release capsule or tablet with the concentration of the active ingredients being that for the total daily dosage. While this invention has been described as having a preferred designs, it is understood that it is capable of further modifi ⁇ ations, uses and/or adaptations of the invention following in general the principle of the invention and including such departures from the present disclosure as come within the known or customary practice in the art to which the invention pertains and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une composition pour le traitement du syndrome prémenstruel comprend une quantité active de calcium, de magnésium, d'un analgésique et d'un diurétique, suffisante pour atténuer les symptômes du syndrome prémenstruel.
PCT/CA1996/000229 1996-04-12 1996-04-12 Composition et procede pour le traitement du syndrome premenstruel Ceased WO1997038701A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CA1996/000229 WO1997038701A1 (fr) 1996-04-12 1996-04-12 Composition et procede pour le traitement du syndrome premenstruel
AU52655/96A AU5265596A (en) 1996-04-12 1996-04-12 Composition and method for the treatment of premenstrual syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1996/000229 WO1997038701A1 (fr) 1996-04-12 1996-04-12 Composition et procede pour le traitement du syndrome premenstruel

Publications (1)

Publication Number Publication Date
WO1997038701A1 true WO1997038701A1 (fr) 1997-10-23

Family

ID=4173147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1996/000229 Ceased WO1997038701A1 (fr) 1996-04-12 1996-04-12 Composition et procede pour le traitement du syndrome premenstruel

Country Status (2)

Country Link
AU (1) AU5265596A (fr)
WO (1) WO1997038701A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841551B2 (en) * 2000-01-18 2005-01-11 Hoffmann-La Roche Inc. Brain, spinal, and nerve injury treatment
EP3127546A1 (fr) * 2015-08-06 2017-02-08 Kenneth Davin Fine Réduction d'absorption d'oxalate chez des individus
WO2018057737A1 (fr) * 2016-09-22 2018-03-29 Cash Alan B Méthode pour soulager les symptômes du spm

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081823A1 (fr) * 1981-12-10 1983-06-22 WHITBY RESEARCH, Inc. Composition pour diminuer les douleurs menstruelles
EP0246177A2 (fr) * 1986-05-14 1987-11-19 George H. Clark Boisson et procédé de production d'une boisson, pour compléter la ration de calcium chez l'homme
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US4946679A (en) * 1988-07-25 1990-08-07 Thys Jacobs Susan Method for the treatment of premenstrual syndrome
CA2150417A1 (fr) * 1994-10-14 1996-04-15 Simon W. Rabkin Composition pour le traitement du syndrome premenstruel et mode d'emploi

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081823A1 (fr) * 1981-12-10 1983-06-22 WHITBY RESEARCH, Inc. Composition pour diminuer les douleurs menstruelles
EP0246177A2 (fr) * 1986-05-14 1987-11-19 George H. Clark Boisson et procédé de production d'une boisson, pour compléter la ration de calcium chez l'homme
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US4946679A (en) * 1988-07-25 1990-08-07 Thys Jacobs Susan Method for the treatment of premenstrual syndrome
CA2150417A1 (fr) * 1994-10-14 1996-04-15 Simon W. Rabkin Composition pour le traitement du syndrome premenstruel et mode d'emploi

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841551B2 (en) * 2000-01-18 2005-01-11 Hoffmann-La Roche Inc. Brain, spinal, and nerve injury treatment
US9186404B2 (en) 2000-01-18 2015-11-17 Eustralis Pharmaceuticals Limited Brain, spinal and nerve injury treatment
US10201568B2 (en) 2000-01-18 2019-02-12 Eustralis Pharmaceuticals Limited Brain, spinal, and nerve injury treatment
EP3127546A1 (fr) * 2015-08-06 2017-02-08 Kenneth Davin Fine Réduction d'absorption d'oxalate chez des individus
WO2018057737A1 (fr) * 2016-09-22 2018-03-29 Cash Alan B Méthode pour soulager les symptômes du spm
JP2019529559A (ja) * 2016-09-22 2019-10-17 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
US11071722B2 (en) 2016-09-22 2021-07-27 Alan B. Cash Method to alleviate the symptoms of PMS
JP7291079B2 (ja) 2016-09-22 2023-06-14 アラン ビー． キャッシュ， Ｐｍｓの症状を軽減する方法
AU2017330348B2 (en) * 2016-09-22 2023-09-07 Alan B. Cash Method to alleviate the symptoms of PMS
US11865092B2 (en) 2016-09-22 2024-01-09 Alan B. Cash Method to alleviate the symptoms of PMS
US12324794B2 (en) 2016-09-22 2025-06-10 Alan B. Cash Method to alleviate the symptoms of PMS

Also Published As

Publication number Publication date
AU5265596A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
US5612061A (en) Composition and method for the treatment of premenstrual syndrome
US6500450B1 (en) Composition for treating migraine headaches
Saper et al. Ergotamine tartrate dependency: features and possible mechanisms
Sharma et al. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium
DE69529213T2 (de) Verwendung von magnesium enthaltenden verbindungen zur behandlung oder prophylaxe von krebs- und autoimmunkrankheiten
US8129430B2 (en) Method of reducing phosphate nephropathy in a mammal
US4387093A (en) Arthritis treatment
US20030125303A1 (en) Transdermal formulation for repair and maintenance of connective tissue
WO1997038701A1 (fr) Composition et procede pour le traitement du syndrome premenstruel
CN1371291A (zh) 用于缓解肿瘤和抑制癌症的方法和制剂
DE3500670A1 (de) Diphosphonate enthaltende arzneimittel
EP1784177B1 (fr) Formulation pour l-tryptophane comprenant du carbidopa-benserazide
JP2024061731A (ja) 片頭痛の予防及び治療に使用するための栄養補助食品
Diamond et al. Fenoprofen in the Prophylaxis of Migraine: A Double—Blind, Placebo Controlled Study
CA1208132A (fr) Compose pour soulager les maux de dents et autres douleurs intenses
EP3693020A1 (fr) Formulations topiques enrichies en potassium pour le soulagement de la douleur et l'aide du sommeil
DE3936319C2 (fr)
DE102022103658A1 (de) Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
US3055805A (en) Process of treating acidosis with t.h.a.m.
JPH061721A (ja) 疼痛処置剤、及び疼痛軽減作用増強剤
EP0018550A2 (fr) Compositions pour le traitement de maladies musculaires
Fazio et al. Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor
Janicak et al. Verapamil for acute mania: preliminary results from a double-blind, placebo-controlled study
US4385064A (en) Method for treating sickle cell anemia
US8039023B1 (en) Composition for relief of menstrual cramps and muscle cramps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536595

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase